​In 2007, the U.S. Patent Office approved U.S. Patent RE42645E/RE39734 (Immune Formulation 200®). This patent, filed by ProImmune® founder and Harvard-trained physician Dr. Albert B. Crum, devised a novel and unprecedented means of achieving optimal glutathione regeneration, even in the presence of significant oxidative stressors, by making use of the biosynthetic pathway present in each eukaryotic cell.

He understood L-Cysteine to be the most important part of that synthetic process, and, further, that the unstable nature of L-Cysteine necessitates its safe import into cells in order to allow its participation in glutathione synthesis.

Dr. Crum’s patent demonstrated that L-Cystine (made of two L-Cysteines bound together) is the optimal physiologic carrier of L-Cysteine, capable of passage into the cell, whereupon the two L-Cysteines can immediately participate in the synthesis of glutathione.

​

Since the initial filing of Patent RE42645E/RE39734, Dr. Crum’s work has produced a portfolio of over twenty new-use and otherwise related patents, all employing his novel method of physiological glutathione production. Given the multifaceted role of glutathione, Dr. Crum’s portfolio is emblematic of the many different areas in which Immune Formulation 200® (which sells under the name ProImmune) can provide advantageous benefits to health and wellbeing. This includes its potential antiviral effects, as documented in the 2019 publication by the Georgia State University Research Foundation.